NASDAQ:APGE Apogee Therapeutics (APGE) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free APGE Stock Alerts $49.00 +1.87 (+3.97%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$47.21▼$49.7750-Day Range$34.50▼$69.8052-Week Range$14.19▼$72.29Volume207,028 shsAverage Volume608,386 shsMarket Capitalization$2.10 billionP/E RatioN/ADividend YieldN/APrice Target$71.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Apogee Therapeutics alerts: Email Address Apogee Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.6% Upside$71.83 Price TargetShort InterestBearish12.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.67) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.52 out of 5 starsMedical Sector689th out of 918 stocksBiological Products, Except Diagnostic Industry114th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingApogee Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageApogee Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.97% of the float of Apogee Therapeutics has been sold short.Short Interest Ratio / Days to CoverApogee Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Apogee Therapeutics has recently decreased by 1.09%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldApogee Therapeutics does not currently pay a dividend.Dividend GrowthApogee Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APGE. Previous Next 2.1 News and Social Media Coverage News SentimentApogee Therapeutics has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Apogee Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 3 people have added Apogee Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apogee Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions79.04% of the stock of Apogee Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Apogee Therapeutics are expected to decrease in the coming year, from ($2.67) to ($3.06) per share.Price to Book Value per Share RatioApogee Therapeutics has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityCharles Payne’s Gift to Stock InvestorsRight now, millions of good honest folks are feeling the squeeze. Last year's terrible market did a number on their accounts. Stock values plunged. Retirement accounts lost too.Watch Insider's Advantage Event Tuesday at 4:00 PM ET About Apogee Therapeutics Stock (NASDAQ:APGE)Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Read More APGE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APGE Stock News HeadlinesApril 16, 2024 | finance.yahoo.comWith 54% institutional ownership, Apogee Therapeutics, Inc. (NASDAQ:APGE) is a favorite amongst the big gunsApril 15, 2024 | finance.yahoo.comApogee Therapeutics, Inc. (APGE)April 29, 2024 | Banyan Hill Publishing (Ad)Nvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.March 29, 2024 | finance.yahoo.comKey Proteo Submits De Novo Application to FDA for its First Newborn Screening KitMarch 28, 2024 | msn.comGov. Youngkin vetoes bills that would legalize retail marijuana sales, increase minimum wageMarch 28, 2024 | finance.yahoo.comUS FDA extends review of Applied Therapeutics' genetic disease drugMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Apogee Therapeutics as APG777 Shows Promise and Pipeline ProgressesMarch 25, 2024 | globenewswire.comApogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory DiseasesApril 29, 2024 | Banyan Hill Publishing (Ad)Nvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.March 14, 2024 | benzinga.comTop 3 Health Care Stocks That Are Ticking Portfolio BombsMarch 13, 2024 | seekingalpha.comARM: Everything You Need To Know About The Lock-Up Expiry (Rating Upgrade)March 12, 2024 | finance.yahoo.comApogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 MillionMarch 12, 2024 | globenewswire.comApogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 MillionMarch 8, 2024 | msn.comApogee Therapeutics stock slides on pricing upsized stock offering to raise $420 millionMarch 8, 2024 | finanznachrichten.deApogee Therapeutics, Inc.: Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | edition.cnn.comApogee Therapeutics, Inc.March 7, 2024 | globenewswire.comApogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public OfferingMarch 6, 2024 | realmoney.thestreet.comApogee Therapeutics price target raised by $47 at Guggenheim, here's whyMarch 6, 2024 | markets.businessinsider.comBuy Rating Endorsed for Apogee Therapeutics Amid Promising APG777 Phase 1 ResultsMarch 6, 2024 | markets.businessinsider.comApogee Therapeutics, Inc. Announces Proposed Underwritten Public OfferingMarch 6, 2024 | msn.comWhy Is Atopic Dermatitis-Focused Apogee Therapeutics Stock Trading Higher On Tuesday?March 6, 2024 | finance.yahoo.comInsiders Of Apogee Therapeutics Reap Rewards After Their Investment Jumps Another US$74mMarch 6, 2024 | seekingalpha.comApogee Therapeutics: Success In Phase 1 Bodes Well For Continued APG777 AdvancementMarch 5, 2024 | investorplace.comAPGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023March 5, 2024 | globenewswire.comApogee Therapeutics, Inc. Announces Proposed Underwritten Public OfferingMarch 5, 2024 | seekingalpha.comApogee Therapeutics' Innovative Leap In Atopic Dermatitis ManagementMarch 5, 2024 | marketwatch.comApogee Therapeutics Shares Gain on Promising Dermatitis Drug TrialSee More Headlines Receive APGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today4/29/2024Next Earnings (Estimated)6/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:APGE CUSIPN/A CIK1974640 Webwww.apogeetherapeutics.com Phone650-394-5230FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price Target$71.83 High Stock Price Target$95.00 Low Stock Price Target$40.00 Potential Upside/Downside+48.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio19.38 Quick Ratio19.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.50 per share Price / Book6.45Miscellaneous Outstanding Shares42,920,000Free FloatN/AMarket Cap$2.08 billion OptionableOptionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Michael Thomas Henderson M.D. (Age 34)CEO & Director Comp: $1.17MMs. Jane Pritchett V. Henderson (Age 58)Chief Financial Officer Comp: $843.64kDr. Carl Linden Dambkowski M.D. (Age 38)Chief Medical Officer Comp: $870.83kDr. Rebecca Dabora Ph.D. (Age 65)Chief Technical Officer Ms. Noel KurdiVice President of Investor RelationsMr. Matthew Batters J.D. (Age 48)General Counsel Ms. Emily CoxVP & Head of PeopleMs. Wendy Aspden-CurranSenior Vice President of Clinical OperationsDr. Drew Badger Ph.D.Senior VP and Head of Regulatory Affairs & ToxicologyMs. Monica Forbes (Age 48)Senior Vice President of Finance More ExecutivesKey CompetitorsArcellxNASDAQ:ACLXImmunocoreNASDAQ:IMCRCG OncologyNASDAQ:CGONVericelNASDAQ:VCELDenali TherapeuticsNASDAQ:DNLIView All CompetitorsInsiders & InstitutionsChina Universal Asset Management Co. Ltd.Bought 1,600 shares on 4/29/2024Ownership: 0.017%Wellington Management Group LLPBought 4,749 shares on 3/5/2024Ownership: 3.141%Blackstone Inc.Bought 52,688 shares on 2/15/2024Ownership: 0.694%Braidwell LPBought 189,988 shares on 2/14/2024Ownership: 1.344%Artia Global Partners LPBought 10,381 shares on 2/14/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions APGE Stock Analysis - Frequently Asked Questions Should I buy or sell Apogee Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apogee Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APGE shares. View APGE analyst ratings or view top-rated stocks. What is Apogee Therapeutics' stock price target for 2024? 7 brokers have issued 1-year price objectives for Apogee Therapeutics' shares. Their APGE share price targets range from $40.00 to $95.00. On average, they predict the company's stock price to reach $71.83 in the next year. This suggests a possible upside of 46.6% from the stock's current price. View analysts price targets for APGE or view top-rated stocks among Wall Street analysts. How have APGE shares performed in 2024? Apogee Therapeutics' stock was trading at $27.94 on January 1st, 2024. Since then, APGE stock has increased by 75.4% and is now trading at $49.00. View the best growth stocks for 2024 here. Are investors shorting Apogee Therapeutics? Apogee Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,600,000 shares, an increase of 50.8% from the March 15th total of 3,050,000 shares. Based on an average daily volume of 680,700 shares, the days-to-cover ratio is currently 6.8 days. Currently, 13.1% of the company's shares are sold short. View Apogee Therapeutics' Short Interest. When is Apogee Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our APGE earnings forecast. How were Apogee Therapeutics' earnings last quarter? Apogee Therapeutics, Inc. (NASDAQ:APGE) released its earnings results on Tuesday, March, 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.13. What ETFs hold Apogee Therapeutics' stock? ETFs with the largest weight of Apogee Therapeutics (NASDAQ:APGE) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). When did Apogee Therapeutics IPO? Apogee Therapeutics (APGE) raised $282 million in an initial public offering on Friday, July 14th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share. Who are Apogee Therapeutics' major shareholders? Apogee Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include China Universal Asset Management Co. Ltd. (0.02%). View institutional ownership trends. How do I buy shares of Apogee Therapeutics? Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:APGE) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsNvidia CEO Says It Will Be “the Next Revolution” Beyond AIBanyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
